SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants-Reference-Cited by-同舟云学术

SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants

Published:2017-05-23 Issue:9 Volume:89 Page:1620-1628
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:J Med Virol

Author:

Jones Meleri¹^ORCID,Cunningham Morven E.¹,Wing Peter¹,DeSilva Sampath¹,Challa Rupa²,Sheri Anjaneyulu²,Padmanabhan Seetharamaiyer²,Iyer Radhakrishnan P.²,Korba Brent E.³,Afdhal Nezam³,Foster Graham R.¹

Affiliation:

1. The Liver Unit; Blizard Institute, Barts Health, Queen Mary University of London; London UK

2. Spring Bank Pharmaceuticals; Milford Massachusetts

3. Department of Microbiology & Immunology; Georgetown University Medical Centre; Washington District of Columbia

Publisher

Wiley

Subject

Infectious Diseases,Virology

Reference31 articles.

1. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection;Feld;N Engl J Med,2015

2. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection;Foster;N Engl J Med,2015

3. Sofosbuvir/Velpatasvir: the first pangenotypic direct-Acting antiviral combination for hepatitis C;Chahine;Ann Pharmacother,2016

4. Ledipasvir/sofosbuvir-based treatment of patients with chronic genotype-1 HCV infection and cirrhosis: results from two Phase II studies;Lawitz;Antivir Ther,2016

5. Prevalence of resistance-Associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir;Sarrazin;Gastroenterology,2016

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ORMDL3 restrains type-I interferon signaling and anti-tumor immunity by promoting RIG-I degradation;2024-08-13

2. RIG-I-like receptors: Molecular mechanism of activation and signaling;Advances in Immunology;2023

3. Long Noncoding RNA XIST Promotes Resistance to Lenvatinib in Hepatocellular Carcinoma Cells via Epigenetic Inhibition of NOD2;Journal of Oncology;2022-10-18

4. Viral-Host Dependency Factors as Therapeutic Targets to Overcome Antiviral Drug-Resistance: A Focus on Innate Immune Modulation;Frontiers in Virology;2022-07-05

5. Therapeutic Interventions Targeting Innate Immune Receptors: A Balancing Act;Chemical Reviews;2021-12-06